Ketamine-Assisted Therapy for PTSD and Trauma

Ketamine therapy for PTSD is an investigational, clinician-supervised approach that may reduce symptoms quickly for some people, but it is not a replacement for established trauma-focused psychotherapy. Small randomized trials of intravenous ketamine have reported short-term improvement in PTSD symptoms, while larger questions remain about who benefits, how long improvement lasts, and whether ketamine meaningfully improves outcomes when paired with therapy.

For people considering this option, the practical question is not simply whether ketamine can affect symptoms. It is whether a qualified clinician can assess safety, explain the limits of the evidence, and integrate treatment with proven PTSD care such as prolonged exposure, cognitive processing therapy, or EMDR.

What the evidence says about ketamine for PTSD

The evidence for ketamine in PTSD is promising but incomplete. In a randomized crossover trial, Feder and colleagues found that a single intravenous ketamine infusion was associated with lower PTSD symptom scores 24 hours later than midazolam in adults with chronic PTSD. The study was small, so it cannot establish the best dose, long-term benefit, or which patients are most likely to respond. Read the 2014 randomized trial on PubMed.

A later randomized trial tested six intravenous ketamine infusions over two weeks in chronic PTSD. Both the ketamine and midazolam groups improved, and the trial did not find a statistically significant overall difference between the groups on its primary PTSD symptom outcome. That result is an important limit on claims that repeated ketamine is a proven PTSD treatment. Read the repeated-infusion trial on PubMed.

According to the National Institute of Mental Health, about 6 of every 100 people in the United States will have PTSD at some point in their lives. PTSD can involve intrusive memories, avoidance, changes in mood and thinking, and heightened arousal. See NIMH information on PTSD.

The 2023 VA/DoD Clinical Practice Guideline suggests against ketamine for PTSD treatment. The guideline reflects uncertainty about sustained benefit and the need to weigh potential harms. That does not end research into ketamine, but it means patients should approach it as an option requiring individualized clinical review rather than an established standard of care. Read the VA/DoD PTSD guideline.

Why ketamine is being studied alongside trauma therapy

PTSD is often marked by persistent fear responses and avoidance that can make trauma-focused treatment difficult to begin or continue. Ketamine acts on the glutamate system, including NMDA receptors, and researchers are studying whether its short-term effects on mood, cognition, and learning could help some patients engage with psychotherapy.

This is a biological rationale, not proof that ketamine-assisted psychotherapy works better than psychotherapy alone. Research and clinical protocols vary widely in ketamine dose, route of administration, timing of therapy, preparation, and follow-up. Those differences make it difficult to compare programs or assume that findings from intravenous research apply to oral, nasal, or other low-dose approaches.

For a fuller explanation of the proposed mechanisms, see neuroplasticity and ketamine. If a program includes preparation and post-session processing, review what integration therapy after ketamine treatment can involve.

What a careful PTSD evaluation should cover

A clinician should first confirm the PTSD diagnosis, current symptoms, treatment history, medications, substance use, medical history, and immediate safety needs. Ketamine may be a poor fit or require added caution for people with psychosis, uncontrolled high blood pressure, certain cardiovascular concerns, significant dissociation, or active substance-use concerns. Individual decisions belong with a licensed clinician who has the full clinical picture.

Dissociation can occur during ketamine treatment. Some therapy models consider temporary psychological distance potentially useful for approaching difficult material, but dissociation can also be distressing or disorienting. A program should explain how it prepares patients, monitors the session, responds to distress, and provides follow-up. Review common ketamine side effects and cardiovascular monitoring during ketamine treatment before discussing options with a clinician.

Who may and may not be a fit

Ketamine may be worth discussing with a specialist for an adult with diagnosed PTSD who has persistent symptoms despite appropriate evidence-based care, understands the uncertainty in the research, and can participate in follow-up treatment. It may also be considered in a research study, where protocols and outcomes are defined in advance.

It is not a self-directed treatment for traumatic memories, a substitute for urgent psychiatric care, or a reason to stop prescribed PTSD treatment without medical guidance. People with acute safety concerns, including thoughts of self-harm, should seek immediate local emergency or crisis support rather than relying on a delayed treatment consultation.

How to make the decision

Start by reviewing first-line PTSD treatments and whether they have been tried with enough support and duration. Then ask whether the goal is rapid symptom relief, improved ability to participate in therapy, or treatment within a research protocol. A credible discussion should include the uncertain durability of benefit, the possibility of side effects, the treatment setting, monitoring, and a clear plan for what happens after each session.

Medication interactions also need review. For example, clinicians may need to consider concurrent sedating medicines, alcohol use, and benzodiazepines before treatment. Read about ketamine and benzodiazepines and ketamine and alcohol safety risks for questions to raise with the prescribing clinician.

Ketamine research is advancing, but the current evidence supports caution and shared decision-making. The most useful next step is a clinical conversation that keeps trauma-focused therapy, symptom tracking, and safety at the center of care.